FDA approvals of these biosimilars started in 2016, but only 1 such product has successfully launched.
Stephanie Pilat, PharmD
Advertisement
Articles by Stephanie Pilat, PharmD
This study highlights one benefit of the integrated health system specialty pharmacy model for patients who are prescribed acalabrutinib.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
Inhaled Insulin Demonstrates Comparable Safety, Lung Function, and Efficacy to Injectable Insulin in Type 1 Diabetes
2
Mind the Gap: Pharmacy’s Future as AI Evolves in Health Care
3
From $200,000 in Student Loan Debt to Becoming a 7-Figure Pharmacist
4
CDC Layoffs Raise Questions About the Future of Public Health Surveillance
5
